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Protocol
AbstrACt
Introduction Pregnancy rates after frozen embryo 
transfer (FET) have improved in recent years and are 
now approaching or even exceeding those obtained 
after fresh embryo transfer. This is partly due to 
improved laboratory techniques, but may also be caused 
by a more physiological hormonal and endometrial 
environment in FET cycles. Furthermore, the risk 
of ovarian hyperstimulation syndrome is practically 
eliminated in segmentation cycles followed by FET and 
the use of natural cycles in FETs may be beneficial for 
the postimplantational conditions of fetal development. 
However, a freeze-all strategy is not yet implemented 
as standard care due to limitations of large randomised 
trials showing a benefit of such a strategy. Thus, there 
is a need to test the concept against standard care in a 
randomised controlled design. This study aims to compare 
ongoing pregnancy and live birth rates between a freeze-
all strategy with gonadotropin-releasing hormone (GnRH) 
agonist triggering versus human chorionic gonadotropin 
(hCG) trigger and fresh embryo transfer in a multicentre 
randomised controlled trial.
Methods and analysis Multicentre randomised, 
controlled, double-blinded trial of women undergoing 
assisted reproductive technology treatment including 424 
normo-ovulatory women aged 18–39 years from Denmark 
and Sweden. Participants will be randomised (1:1) to 
either (1) GnRH agonist trigger and single vitrified-warmed 
blastocyst transfer in a subsequent hCG triggered natural 
menstrual cycle or (2) hCG trigger and single blastocyst 
transfer in the fresh (stimulated) cycle. The primary 
endpoint is to compare ongoing pregnancy rates per 
randomised patient in the two treatment groups after the 
first single blastocyst transfer.
Ethics and dissemination The study will be performed 
in accordance with the ethical principles in the Helsinki 
Declaration. The study is approved by the Scientific Ethical 
Committees in Denmark and Sweden. The results of the 
study will be publically disseminated.
trial registration number NCT02746562; Pre-results.
IntroduCtIon
The use of assisted reproductive technology 
(ART) is increasing and presently up to 5% 
of birth cohorts in certain countries are 
conceived by ART.1 In recent years, preg-
nancy rates following frozen embryo transfer 
(FET) have rapidly increased and may now 
be a viable and appropriate alternative to 
the conventional fresh embryo transfer in 
strengths and limitations of this study
 ► The design: A multicentre, randomised controlled 
double-blinded trial powered to identify an increase 
in ongoing pregnancy rate in the freeze-all group 
compared with the conventional fresh blastocyst 
transfer group.
 ► The study includes normo-ovulatory women aged 
18–39 years with a body mass index  <35; thus, 
results can be extrapolated to the majority of the 
normo-ovulatory infertile population.
 ► Gonadotropin-releasing hormone (GnRH) agonist 
trigger in the freeze-all group adds a concept of an 
ovarian hyperstimulation syndrome   (OHSS)-free 
strategy.
 ► As both GnRH-agonist trigger and elective freeze-all 
are new treatment approaches, we will not be able 
to distinguish the two effects from each other, but 
compare an OHSS-free strategy with a conventional 
fresh transfer strategy.
 ► The study is powered to detect a 13% difference 
in ongoing pregnancy between the two groups; 
thus,  smaller but yet clinically relevant differences 
may be overlooked.
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ART. The main reason is the introduction of vitrifica-
tion, increasing post-thawing survival rates after blastocyst 
culture significantly as compared with previous years.2 3 
Implantation as well as clinical and ongoing pregnancy 
rates are correspondingly improving in frozen cycles and 
approaching or even exceeding those associated with 
fresh embryo transfer.4–6
A freeze-all strategy has been suggested as a way to 
further improve success rates in ART, arguing that the 
use of the best embryo in frozen cycles instead of in fresh 
cycles may potentially increase pregnancy rates and live 
birth rates.6 7 The rationale is that transfer of a frozen-
thawed embryo in a subsequent natural menstrual cycle 
has the advantage of an endometrium that has not been 
exposed to the supraphysiological levels of estradiol and 
progesterone following controlled ovarian stimulation 
(COS) in fresh cycles, which may negatively affect endo-
metrial receptivity.5 8Elective FET (eFET) moreover has 
the benefit of essentially eliminating the risk of devel-
oping late ovarian hyperstimulation syndrome (OHSS) 
associated with the pregnancy-related rise in human 
chorionic gonadotropin (hCG) levels.9 If ovulation is 
induced with a gonadotropin-releasing hormone (GnRH) 
agonist instead of hCG and all embryos are frozen, even 
early OHSS is minimised making the overall OHSS risk 
extremely low.10 Freezing and thawing of embryos addi-
tionally encourages an elective single embryo transfer 
policy with cumulative pregnancy rates similar to those 
seen after double embryo transfer.11 12
Despite evidence suggesting that ART outcomes may 
be further improved with the adaptation of a freeze-all 
strategy, the implementation remains a topic of ongoing 
debate and only one in five transfers in Europe on average 
was performed with frozen-thawed embryos in 2012.1 In a 
large recent study, including 1508 patients with polycystic 
ovary syndrome (PCOS) comparing the freeze-all strategy 
with conventional fresh embryo transfer, the authors 
found a significantly higher frequency of live birth 
after the first FET compared with fresh embryo transfer 
(49.3% vs 42.0%).7 Correspondingly, in a meta-analysis 
including three trials accounting for 633 cycles in women 
aged 27–33 years, eFET resulted in significantly higher 
clinical and ongoing pregnancy rates compared with 
fresh embryo transfer.6 However, the included studies 
showed heterogeneity and one of the included publica-
tions was later retracted due to serious methodological 
flaws. In addition, the vast majority of the participants 
were high responders (496 out of 633) accounting for 
a highly selected group of patients, mostly consisting of 
patients with PCOS or patients with and polycystic ovar-
ian-like morphology.6 Moreover, previous studies were 
performed in China, the USA and Japan making them 
less generalisable to a European ART setting. According 
to  Clinicaltrials. gov, there are a few ongoing European 
randomised controlled trials (RCTs) on the freeze-all 
strategy; however, none of these studies investigate an 
almost complete OHSS-free strategy including GnRH-ag-
onist trigger in the freeze-all group.
OHSS is one of the most severe side effects of ART 
and is potentially life threatening. The present protocol 
describes a randomised trial assessing a new ART treat-
ment strategy, where OHSS can be almost completely 
avoided. The results are very important as the majority 
of our patients could avoid the OHSS risk by applying 
the ‘GnRH agonist and freeze-all’ strategy, maybe even 
with a higher chance of pregnancy. This concept has not 
been assessed before and should relevantly be consid-
ered when planning studies investigating the freeze-all 
strategy underlining the need for large multicentre 
RCTs exploring the GnRH agonist and freeze-all strategy 
in a broad population of ART patients. The present study 
will explore this approach in a bi-national multicentre 
RCT setting providing information on the prospect of a 
freeze-all strategy.
objectives
Primary objective
The primary objective of the study is to investigate if 
the ongoing pregnancy rate per randomised patient 
after the first potential single blastocyst transfer is supe-
rior in a freeze-all and transfer later strategy compared 
with the conventional hCG trigger and fresh transfer 
strategy.
Ongoing pregnancy rate is defined as an intrauterine 
pregnancy with a fetal heart beat at transvaginal ultra-
sound in gestational week 7–8.
Ongoing pregnancy rate per first blastocyst transfer is 
also considered as a primary aim of the study addressing 
possible differences in endometrial receptivity between 
the two groups.
Secondary objectives
Secondary objectives include:
1. To assess cumulative live birth rates after one complete 
treatment cycle including consecutive single blastocyst 
transfers of all embryos deriving from that oocyte 
retrieval (fresh and frozen) in the two study groups;
2. To assess the transfer cancellation rate in the two 
study groups;
3. To assess the prevalence of OHSS in the two study 
groups;
4. To compare neonatal outcomes (preterm birth, 
low birth weight, small-for-gestational age, large-
for-gestational age and perinatal mortality) and the 
incidence of pre-eclampsia in the two study groups;
5. To measure time-to-pregnancy from the date of start 
of COS to the date of the first ongoing pregnancy in 
the two study groups;
6. To assess quality of life for both female and male 
partners during the two treatment protocols;
7. To assess physical well-being by way of questionnaires 
and VAS scores regarding pain and discomfort at 4 
and 16 days after oocyte retrieval in the two study 
groups.
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MeThods and analysis
study design
The study is designed as a multicentre randomised, 
controlled double-blinded trial with seven fertility clinics 
in Denmark and Sweden participating. All seven clinics 
are part of a University Hospital setting and perform 
standardised treatments according to the public health-
care system in Denmark and Sweden. Patient enrolment 
started in May 2016 and the last patients are expected to 
be included in the study in May 2018 with the primary 
outcome measure, ongoing pregnancy rate, being known 
for these patients approximately 4 months later for the 
patients allocated to the freeze-all group.
study population/participants and recruitment
The study participants will consist of women and their 
partners initiating ART treatment at one of the seven 
participating public clinics in Denmark and Sweden. 
Before initiating treatment, patients will attend an infor-
mation meeting, where they will be informed about the 
standard ART procedures, treatment regimens as well 
as ongoing clinical studies at the treatment sites. Those 
patients not able to participate in the information meeting 
will instead be informed by a doctor at an outpatient 
clinic consultation. Recruitment will be carried out by the 
doctors and study nurses at the fertility clinics. Prior to 
the initiation of treatment, patient files will be browsed 
by investigators at the clinics to assess if the patient fulfils 
the immediate inclusion criteria. Screening, including 
ultrasound examination of the uterus and ovaries is done 
on menstrual cycle day 2 or 3 securing that all inclusion 
criteria are met. Patients fulfilling the study criteria will 
start COS using a GnRH antagonist cotreatment in accor-
dance with the standard routines of the trial site.
Eligibility criteria
To participate in the study, women will be required to 
meet the following inclusion criteria: female age 18–39 
years; eligibility to initiate the first, second or third ART 
cycle with oocyte aspiration (in vitro fertilisation (IVF) or 
intracytoplasmic sperm injection (ICSI)); Anti-Müllerian 
Hormone (AMH) level > 6.28 pmol/L (Roche Elecsys 
assay) corresponding to the AMH threshold level used 
in the Bologna criteria to characterise poor responders; 
regular menstrual cycle ≥24 days and ≤35 days: body mass 
index (BMI) 18–35 kg/m2; preservation of both ovaries 
and capability of signing informed consent. For specific 
exclusion criteria, see box 1.
randomisation and blinding
Patients who meet the inclusion criteria are randomised 
1:1 to one of the two treatment groups: (1) freeze-all 
including GnRH agonist trigger, blastocyst vitrification 
and subsequent FET in an hCG-triggered natural cycle or 
(2) traditional hCG trigger and fresh blastocyst transfer.
The randomisation is carried out by a study nurse or 
a non-treating doctor using a computerised randomis-
ation programme that runs a minimisation algorithm, 
initially seeded using a random block sequence for 
the first subjects. The minimisation algorithm is 
balancing the following variables: female age (mean and 
frequency of age ≥37 years), previously performed cycles 
(frequency of 0/1/2 cycles), nulliparous (frequency of 
yes/no), fertilisation method (frequency of IVF/ICSI), 
smoking (frequency of yes/no), AMH (≤12 pmol/L, 
13–28 pmol/L, >28 pmol/L) and mean BMI. It selects 
with high (but less than 1.0) probability the treatment 
arm that provides the optimal balance between the arms. 
It also enforces predefined maximum allowed differences 
in number of subjects in each treatment arm at each study 
site (fertility clinic) and within the whole study.
Furthermore, the starting dose of follicular-stimu-
lating hormone (FSH) is entered into the randomisation 
programme before randomisation is performed to make 
sure that the FSH dose is decided on before randomis-
ation. Both the treating consultants and patients are 
blinded to the randomisation results during the COS 
until the day when ovulation trigger is planned.
treatment arms and interventions
The short GnRH antagonist protocol and blastocyst 
culture is applied in both treatment arms. The starting 
dose and type of gonadotropin is decided by the doctor 
on stimulation day 1 (cycle day 2 or 3) and entered into 
the randomisation programme prior to randomisation. 
Individualised gonadotropin dosing based on AMH, age, 
weight, previous COH cycles are applied. Recombinant 
FSH (rFSH) or human menopausal gonadotropin (hMG) 
can be used according to the preference of the site, but 
the daily dose cannot exceed 300 IU. The gonadotropin 
stimulation will be performed according to the routine 
in the clinics and can be changed during the treatment 
according to the ovarian response to stimulation evalu-
ated through ultrasound examination. GnRH antagonist 
cotreatment is initiated at a daily dose of 0.25 mg on stim-
ulation day 5 or 6 according to the general standards in 
each clinic and is continued throughout the rest of the 
gonadotropin stimulation period.
Ultrasound examination is performed on cycle day 2 
or 3 (baseline), stimulation day 6 or 7 and subsequently 
every second to third day until ovulation trigger is decided 
box 1 specific exclusion criteria
 ► Endometriosis stage III to IV
 ► Ovarian cysts with a diameter >30 mm at day of start of stimulation
 ► Submucosal fibroids
 ► Women with severe comorbidity (insulin-dependent diabetes 
mellitus, non-insulin-dependent diabetes mellitus, gastrointestinal, 
cardiovascular, pulmonary, liver or kidney disease)
 ► Dysregulated thyroid disease
 ► Non-Danish or English speaking
 ► Contraindications or allergies to use of gonadotropins or 
gonadotropin-releasing hormone antagonists
 ► Testicular sperm aspiration
 ► Oocyte donation
 ► Previous inclusion in the study
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according to the hCG/GnRH agonist trigger criterion: as 
soon as three follicles are ≥17 mm or 1 day later. At baseline, 
a comprehensive ultrasound examination will estimate 
endometrial thickness, ovarian volume as well as number 
and size of antral follicles divided into the following three 
subclasses: 2–4 mm, 5–7 mm and 8–10 mm. On the day of 
ovulation trigger, endometrial thickness and morphology 
as well as follicular development with number and size of 
follicles>10 mm are registered.
When ovulation trigger is decided, the result of the 
randomisation is disclosed to both doctors and patients 
and ovulation and oocyte maturation is triggered with a 
GnRH agonist trigger injection (0.5 mg buserelin) in the 
freeze-all group or a single injection of 250 µg of hCG 
in the fresh embryo transfer group. If >18 follicles with 
a diameter >11 mm are observed in the fresh embryo 
transfer group GnRH agonist triggering with buserelin 
and vitrification of all embryos will be performed to 
avoid severe OHSS. All fertilised oocytes are cultured 
to the blastocyst stage and the embryos are scored and 
ranked according to standardised criteria ascribed to 
this study. The ranking will assure that the blastocyst with 
the highest implantation potential is transferred first in 
both groups. In the fresh transfer group, single blasto-
cyst transfer is performed on day 5 after oocyte retrieval 
if a good-quality blastocyst has developed. Surplus good 
quality blastocysts will be vitrified on day 5 or 6. Luteal 
phase support is administered as vaginal progesterone 
according to the clinics standard procedures from day 
2 after oocyte retrieval until the day of hCG test; thus, 
luteal support is not extended into early pregnancy. In 
the freeze-all group, all blastocysts of good quality are 
vitrified on day 5 or 6 depending on when the blastocyst 
stage is reached. The blastocyst with the highest rank is 
marked and will be the first one used in a subsequent 
hCG-triggered modified natural FET cycle. There should 
be at least one completed menstrual cycle in between the stimula-
tion and the embryo transfer. In FET cycles, a single injection 
of 250 µg hCG is administered, when the leading follicle 
is >17 mm. Blastocyst transfer is performed 6 or 7 days 
after the hCG injection. No luteal phase support is given.
A plasma hCG test is performed 11 days after blastocyst 
transfer. Ongoing clinical pregnancy is defined as fetal 
heart beat at gestational age 7–8 confirmed by transvag-
inal ultrasound 3–4 weeks after a positive plasma hCG 
test. For overview of study design, see figure 1.
data collection and management
Treatment-related data are collected at (1) baseline (cycle 
day 2 or 3), (2) day of ovulation trigger and (3) 5 days 
after oocyte retrieval. Data on blastocysts are collected 
at culture day 5/6. Follow-up data on all pregnancies 
resulting from blastocysts transferred according to the 
study protocol will be followed from study inclusion and 
1 year onwards. Data are transferred to an online eCRF 
system called MediCase with an underlying Microsoft 
SQL server database located in a guarded underground 
facility in Sweden. Data are backed up daily (one backup 
to another computer in the same physical location as the 
server and a second backup to a physically separate loca-
tion, also in Sweden). MediCase has a complete audit trail 
and is designed to only contain de-identified data and is 
entirely based on anonymous subject ID numbers used in 
the trial.
sample collection
Blood samples will be collected three times during the 
treatment process: (1) baseline (cycle day 2 or 3), (2) 
day of ovulation trigger and (3) 16 days after oocyte 
retrieval (day of pregnancy test in the fresh embryo 
transfer group). For overview of samples, see table 1. 
Furthermore, one serum, plasma and full-blood sample 
are drawn at baseline and on the day of triggering and 
stored according to a trial specific laboratory manual 
in a project-specific biobank as backup for analysis of 
endocrine and immunological factors of relevance for 
pregnancy. The frozen samples will be kept anonymised 
in the biobank with only the patient-specific project ID 
number and collection date marked on the sample. The 
samples will be stored in the participating fertility clinics 
and destroyed 5 years after the end of the study period if 
not analysed.
Further blood samples will be collected during the 
luteal phase for a smaller subgroup of 60 patients,30 in 
each treatment group as part of a luteal phase subgroup 
analysis of differences in hormone levels in the two 
groups. The following blood samples will be collected 
at (1) day of ovulation trigger and (2) day of ovulation 
trigger, day of ovulation trigger +7, +11, +14, +16 and +
19: estradiol, inhibin-A, OH-progesterone, progesterone, 
luteinising hormone and hCG.
Figure 1 Flowchart of the freeze-all study design. hCG, 
human chorionic gonadotropin; GnRH, gonadotropin-
releasing hormone.
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Questionnaires
Women as well as male partners will be asked to fill in 
quality-of-life-validated questionnaires twice during the 
treatment process: (1) 4 days after oocyte retrieval and (2) 
16 days after oocyte retrieval. The questionnaires consist 
of standardised questions specially developed to explore 
emotional aspects as well as quality-of-life-related aspects 
of the treatment process. The women will at the same 
time be asked to fill in questionnaires regarding physical 
discomfort including a Visual Analog Scale (VAS) score of 
physical pain in relation to the treatment.
statistics
Sample size calculation
The trial is designed as a superiority study. Sample 
size calculation indicates that 424 participants (n=212 
in each arm) are required to have a 80% chance of 
detecting, at a significance level at 0.05, an increase in 
the primary outcome measure (ongoing pregnancy rate 
per randomised patient after the first potential blastocyst 
transfer) from 30% in the control group (fresh embryo 
transfer) to 43% in the experimental group (freeze-all).
Outcome measurements (primary and secondary)
The primary endpoint is the ongoing pregnancy rate per 
randomised patient after the transfer of the first potential 
blastocyst. Ongoing pregnancy is defined as a pregnancy 
with a positive fetal heart beat at gestational week 7–8.
Other endpoints explored in the study contribute 
to the assessment of other relevant aspects of the 
freeze-all strategy including ongoing pregnancy rates per 
transfer, per started stimulation and per oocyte pick-up 
(percentage of participants with an ultrasound confirma-
tion of fetal heart beat at gestational age 7–8) as well as 
live birth rate and cumulative live birth rates (percentage 
of participants with one live born neonate after 1 year of 
follow-up). The study furthermore aims to document the 
prevalence of OHSS assessed by the number of patients 
admitted to hospital under this diagnosis and the number 
of patients having ascites puncture. In addition, it is 
planned to evaluate pregnancy-related complications as 
well as neonatal outcomes in both groups. For complete 
overview of all secondary endpoint measures, see box 2.
Statistical analyses
Analyses of cumulative pregnancy rates and live birth 
rates after one oocyte retrieval including fresh and all 
FET cycles will be compared by Cox-regression anal-
yses. Comparisons between treatment groups will be 
performed primarily according to the intention-to-treat 
Table 1 Blood sample collection
Baseline (cycle day 2 or 3) AMH
FSH
LH
Estradiol
Progesterone
TSH
TPO antibodies
Vitamin D
CRP
suPAR*
Day of ovulation induction FSH
LH
Estradiol
Progesterone
CRP
suPAR*
16 days after oocyte retrieval CRP
suPAR*
hCG†
*suPAR only measured at Hvidovre Hospital.
†Only fresh embryo transfer group.
AMH, anti-mullerian hormone; CRP, C reactive protein; 
FSH, follicular-stimulating hormone; hCG, human chorionic 
gonadotropin; LH, luteinising hormone; suPAR, soluble urokinase 
plasminogen activator receptor; TPO, thyroperoxidase; TSH, 
thyroid-stimulating hormone.
box 2 secondary endpoints
 ► Ongoing pregnancy rate per start of per started ovarian stimulation 
and per oocyte retrieval
 ► Live birth rate after the first blastocyst transfer calculated per 
randomised patient, per started ovarian stimulation, per oocyte 
retrieval and per transfer
 ► Cumulative live birth rate after one stimulated cycle with oocyte 
retrieval
 ► Cumulative live birth rate after use of all frozen blastocyst or after at 
least 1 year of follow-up
 ► Number of cycles with no embryo transfer
 ► Time-to-pregnancy (from start of ovarian stimulation to positive 
human chorionic gonadotropin (hCG))
 ► Time-to-delivery
 ► Cancelled embryo transfers
 ► Ovarian hyperstimulation syndrome
 ► Preterm birth
 ► Low birth weight
 ► Small-for-gestational age
 ► Large-for-gestational age
 ► Perinatal mortality
 ► Pre-eclampsia
 ► Placental rupture
 ► Positive hCG 11 days post embryo transfer
 ► Miscarriage, biochemical pregnancies, ectopic pregnancies
 ► Quality of life for female and male partner
 ► Cost-effectiveness
other outcome measurements
 ► Number of good blastocysts
 ► Number of fertilised oocytes
 ► Number of high quality embryos day 2
 ► Number of grade 1 blastocysts
 ► Number of frozen blastocyst
 ► Paraclinical data: endocrine, genetic and immunological parameters
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(ITT) principle but per-protocol analyses will also be 
done. Continuous data will be compared by students 
t-test or Mann-Whitney U test and Kruskal-Wallis test as 
appropriate. Proportions will be compared with χ² test. 
Predictive factors for ongoing pregnancy in the two 
treatment groups will be tested with multivariate logistic 
regression analyses. A p value of <0.5 will be considered as 
statistically significant.
Patients in fresh embryo transfer group with GnRH agonist 
triggering
Patients allocated to the fresh transfer group who end 
up receiving GnRH agonist trigger and vitrification of 
all blastocysts due to risk of OHSS (>18 follicles with a 
diameter >11 mm on trigger day) will still be analysed 
as part of the fresh transfer group according to the ITT 
principle. Their first blastocyst transfer will derive from 
their first FET cycle and ongoing pregnancies from these 
first transfers will be included in the numerator together 
with ongoing pregnancies derived from the majority of 
patients with first blastocyst transfer in the fresh cycle. 
The denominator will be all randomised patients.
Following oral and written information outlining the 
rationale, trial design, aims and treatment procedures, 
written informed consent will be obtained from female 
and male partners prior to the enrolment in the study.
The participants are stimulated using individualised 
doses of gonadotropin stimulation in accordance with the 
clinical practice at each site. In all clinics serum, AMH is 
considered when the FSH dose is determined. All medi-
cines used in the study are part of standard ART care.
The overall safety of the patients is high in both treat-
ment groups. The risk of OHSS is expected to be similar 
to the standard clinical protocol in the fresh embryo 
transfer group and lower in the freeze-all group in which 
GnRH agonist is used for ovulation trigger. In women 
in the fresh embryo transfer group with a risk of OHSS 
development (more than 18 follicles with a diameter over 
11 mm), GnRH agonist will be used for trigger instead of 
hCG and all blastocysts will be vitrified and the transfer 
postponed.
No financial incentive exists for the participants as all 
couples are reimbursed for their first three ART treat-
ments in the public healthcare system in the Nordic 
countries.
The results of the study will be publicly disseminated in 
peer-reviewed scientific journals and presented at relevant 
international scientific meetings such as ESHRE (Euro-
pean Society of Human Reproduction and Embryology) 
and ASRM (American Society for Reproductive Medi-
cine). In addition, results will be published in popular 
science journals and other media.
dIsCussIon
The increasing interest in possible benefits of a freeze-all 
strategy and the limitations of existing RCTs comparing 
this strategy with conventional fresh embryo transfer 
underlines the need for additional studies. The few 
previous RCTs have demonstrated significantly increased 
pregnancy and delivery rates with freeze-all; however, these 
studies were performed in highly selected patient popula-
tions with poor generalisability.6 7 Further, the treatment 
strategy combining GnRH agonist trigger and freeze-all 
minimising the risk of severe OHSS development has not 
yet been investigated in a RCT setting. As GnRH agonist 
trigger does not hamper the yield of mature oocytes12 
and reduces the risk of OHSS to an absolutely minimum, 
it seems rational to include GnRH agonist trigger in the 
freeze-all concept. Evidently, we are unable to distinguish 
between the effect of the GnRH-agonist trigger and the 
effect of elective freeze-all, when both are included in 
the freeze-all treatment arm. The present study therefore 
compares an ‘OHSS-free’ freeze-all strategy including 
GnRH agonist trigger with a fresh transfer strategy 
with hCG trigger. In both treatment arms individual-
ised gonadotropin dosing is used with the possibility of 
conversion to GnRH agonist trigger and segmentation in 
case of risk of OHSS development in the fresh embryo 
transfer group. Individualised gonadotropin dosing 
based on female age and weight, antral follicle count, 
AMH and results of previous COH cycles is applied, as 
this is the standard treatment approach used routinely in 
all of the participating clinics. The AMH cut-off value at 
6.28 pmol/L (Roche Elecsys assay) corresponding to the 
Bologna criteria for poor ovarian response was chosen to 
have a reasonable chance of the patient ending up with 
at least one usable blastocyst after aspiration. It could be 
argued that an open randomisation, rather than a double-
blinded study design, would allow a better exploration 
of the concept as higher gonadotropin doses and more 
oocytes could be safely aimed for in the freeze-all group. 
However, as this is the first RCT of a freeze-all strategy 
including GnRH agonist trigger, a double-blinded design 
was chosen to minimise differences between the two 
treatment arms and gonadotropin dosing is decided on 
independently of allocation to treatment group, as this is 
done prior to randomisation. In addition, even though a 
strategy combining GnRH agonist trigger and freeze-all is 
near OHSS free, increasing gonadotropin dosing would 
nonetheless add a potential risk of early OHSS in the 
patients.
The primary endpoint of this study is to investigate 
ongoing pregnancy rates per randomised patient after 
the first potential blastocyst transfer. Cumulative rates are 
additionally planned to be calculated, but as the number 
of aspirated oocytes is expected to be the same in both 
treatment groups due to gonadotropin dosing being 
decided on independently of allocated treatment group, 
the effect of the freeze-all strategy on the results of the 
first transfer may be diluted with the inclusion of addi-
tional FETs.
The strengths of this study include the design as a multi-
centre randomised controlled double-blinded trial as well 
as preregistration and publication of the study protocol 
for more transparency. The investigation of several 
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outcome measures related to different aspects of success 
parameters, including quality of life may furthermore add 
important information as regards the future potential of 
the freeze-all strategy in assisted reproduction.
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